• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Aug 1994; 94(2): 585–591.
PMCID: PMC296134

Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Abstract

To investigate the role of IL-6 in systemic lupus erythematosus (SLE), we selectively inhibited IL-6 in lupus-prone NZB/NZW F1(B/W) mice by chronic administration of a rat mAb to mouse IL-6. Anti-IL-6 alone elicited an anti-rat response that blocked its biologic effects. To circumvent this problem, we rendered B/W mice tolerant to the rat mAb by administration of anti-CD4 concurrent with the first dose of anti-IL-6. Thereafter, the mice received weekly injections of anti-IL-6 alone. There were two control groups: one group received the tolerizing regimen of anti-CD4 along with a control rat IgG1 mAb (GL113) instead of anti-IL-6; the other control group received PBS. Mice that received anti-CD4 were tolerant to the rat mAb for 6 mo. Throughout this period, treatment with anti-IL-6 prevented production of anti-dsDNA, significantly reduced proteinuria, and prolonged life. Mice that received anti-IL-6 without anti-CD4 developed an immune response to the rat mAb and then developed anti-dsDNA antibodies, proteinuria, and mortality comparable with control mice. These findings establish that IL-6 promotes autoimmunity in B/W mice. They further indicate that, although mAb to IL-6 can suppress murine lupus, the development of host immunity to the mAb abrogates its beneficial effects. Finally, this is the first study to demonstrate that a brief course of anti-CD4 can induce tolerance to another therapeutic mAb, in this case an anti-cytokine mAb.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hirano T, Teranishi T, Lin B, Onoue K. Human helper T cell factor(s). IV. Demonstration of a human late-acting B cell differentiation factor acting on Staphylococcus aureus Cowan I-stimulated B cells. J Immunol. 1984 Aug;133(2):798–802. [PubMed]
  • Van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie PG, Rubira MR, Simpson RJ. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9679–9683. [PMC free article] [PubMed]
  • Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986 Nov 6;324(6092):73–76. [PubMed]
  • Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun KH, Kishimoto T. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985 Aug;82(16):5490–5494. [PMC free article] [PubMed]
  • Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988 Feb 1;167(2):332–344. [PMC free article] [PubMed]
  • Takai Y, Wong GG, Clark SC, Burakoff SJ, Herrmann SH. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol. 1988 Jan 15;140(2):508–512. [PubMed]
  • Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988 Sep 1;141(5):1543–1549. [PubMed]
  • Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251–7255. [PMC free article] [PubMed]
  • Baumann H, Jahreis GP, Sauder DN, Koj A. Human keratinocytes and monocytes release factors which regulate the synthesis of major acute phase plasma proteins in hepatic cells from man, rat, and mouse. J Biol Chem. 1984 Jun 10;259(11):7331–7342. [PubMed]
  • Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9035–9039. [PMC free article] [PubMed]
  • Wong GG, Witek-Giannotti JS, Temple PA, Kriz R, Ferenz C, Hewick RM, Clark SC, Ikebuchi K, Ogawa M. Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol. 1988 May 1;140(9):3040–3044. [PubMed]
  • MacCarthy EP, Hsu A, Ooi YM, Ooi BS. Modulation of mouse mesangial cell proliferation by macrophage products. Immunology. 1985 Dec;56(4):695–699. [PMC free article] [PubMed]
  • Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, Fujii Y, Dohi K, Ishikawa H, Ohmoto Y, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol. 1989 Dec 15;143(12):3949–3955. [PubMed]
  • Aarden LA, De Groot ER, Schaap OL, Lansdorp PM. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987 Oct;17(10):1411–1416. [PubMed]
  • Alarcón-Riquelme ME, Möller G, Fernández C. Macrophage depletion decreases IgG anti-DNA in cultures from (NZB x NZW)F1 spleen cells by eliminating the main source of IL-6. Clin Exp Immunol. 1993 Feb;91(2):220–225. [PMC free article] [PubMed]
  • Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq H, Nir U, Wallach D, Perricaudet M, Tiollais P, Revel M. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7152–7156. [PMC free article] [PubMed]
  • Hültner L, Szöts H, Welle M, Van Snick J, Moeller J, Dörmer P. Mouse bone marrow-derived IL-3-dependent mast cells and autonomous sublines produce IL-6. Immunology. 1989 Jul;67(3):408–413. [PMC free article] [PubMed]
  • Horii Y, Muraguchi A, Suematsu S, Matsuda T, Yoshizaki K, Hirano T, Kishimoto T. Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells. J Immunol. 1988 Sep 1;141(5):1529–1535. [PubMed]
  • Freeman GJ, Freedman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, Whitman JF, Nadler LM. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989 May;83(5):1512–1518. [PMC free article] [PubMed]
  • Corbel C, Melchers F. The synergism of accessory cells and of soluble alpha-factors derived from them in the activation of B cells to proliferation. Immunol Rev. 1984 Apr;78:51–74. [PubMed]
  • Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatsuki F, Shimizu M, Murashima A, Tsunasawa S, Sakiyama F, et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A. 1987 Jan;84(1):228–231. [PMC free article] [PubMed]
  • Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988 Nov;18(11):1797–1801. [PubMed]
  • Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988 Jun;31(6):784–788. [PubMed]
  • Gordon C, Richards N, Howie AJ, Richardson K, Michael J, Adu D, Emery P. Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol. 1991 Oct;86(1):145–149. [PMC free article] [PubMed]
  • Campbell IL, Harrison LC. A new view of the beta cell as an antigen-presenting cell and immunogenic target. J Autoimmun. 1990 Apr;3 (Suppl 1):53–62. [PubMed]
  • Campbell IL, Harrison LC. Molecular pathology of type 1 diabetes. Mol Biol Med. 1990 Aug;7(4):299–309. [PubMed]
  • Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991 Jul 1;147(1):117–123. [PubMed]
  • Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol. 1992 Apr;63(1):10–12. [PubMed]
  • Metsärinne KP, Nordström DC, Konttinen YT, Teppo AM, Fyhrquist FY. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int. 1992;12(3):93–96. [PubMed]
  • Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CG. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol. 1992 Oct;90(1):106–110. [PMC free article] [PubMed]
  • Swaak AJ, van Rooyen A, Aarden LA. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int. 1989;8(6):263–268. [PubMed]
  • al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. 1993 Jan;13(1):58–67. [PubMed]
  • Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990 May;33(5):644–649. [PubMed]
  • Hirose T, Hara M, Kitani A, Hirose W, Norioka K, Kawagoe M, Nakamura H. Abnormal production of and response to B-cell growth factor and B-cell differentiation factor in patients with systemic lupus erythematosus. Scand J Immunol. 1985 Feb;21(2):141–150. [PubMed]
  • Kitani A, Hara M, Hirose T, Harigai M, Suzuki K, Kawakami M, Kawaguchi Y, Hidaka T, Kawagoe M, Nakamura H. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol. 1992 Apr;88(1):75–83. [PMC free article] [PubMed]
  • Kitani A, Hara M, Hirose T, Norioka K, Harigai M, Hirose W, Suzuki K, Kawakami M, Kawagoe M, Nakamura H. Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. Clin Exp Immunol. 1989 Jul;77(1):31–36. [PMC free article] [PubMed]
  • Tanaka Y, Saito K, Shirakawa F, Ota T, Suzuki H, Eto S, Yamashita U. Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus. J Immunol. 1988 Nov 1;141(9):3043–3049. [PubMed]
  • Pelton BK, Hylton W, Denman AM. Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 1992 Aug;89(2):251–254. [PMC free article] [PubMed]
  • Vandenabeele P, Abramowicz D, Berus D, Van der Heyden J, Grooten J, Donckier V, Hooghe-Peters EL, Goldman M, Fiers W. Increased IL-6 production and IL-6-mediated Ig secretion in murine host-vs-graft disease. J Immunol. 1993 May 1;150(9):4179–4187. [PubMed]
  • Campbell IL, Kay TW, Oxbrow L, Harrison LC. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest. 1991 Feb;87(2):739–742. [PMC free article] [PubMed]
  • Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7547–7551. [PMC free article] [PubMed]
  • Woodroofe C, Müller W, Rüther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 1992 Oct;11(8):587–592. [PubMed]
  • Tang B, Matsuda T, Akira S, Nagata N, Ikehara S, Hirano T, Kishimoto T. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol. 1991 Mar;3(3):273–278. [PubMed]
  • Emmendörffer A, Müller M, Wedekind D, Hartung K, Lohmann-Matthes ML. Expansion of the liver-associated macrophage system in systemic lupus erythematosus-prone NZB/W mice. J Leukoc Biol. 1993 Mar;53(3):294–300. [PubMed]
  • Alarcón-Riquelme ME, Möller G, Fernández C. Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB x NZW)F1 hybrid. Clin Immunol Immunopathol. 1992 Mar;62(3):264–269. [PubMed]
  • Mihara M, Fukui H, Koishihara Y, Saito M, Ohsugi Y. Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6. Clin Exp Immunol. 1990 Dec;82(3):533–537. [PMC free article] [PubMed]
  • Herron LR, Coffman RL, Kotzin BL. Enhanced response of autoantibody-secreting B cells from young NZB/NZW mice to T-cell-derived differentiation signals. Clin Immunol Immunopathol. 1988 Feb;46(2):314–327. [PubMed]
  • Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. [PMC free article] [PubMed]
  • Gutstein NL, Wofsy D. Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. J Immunol. 1986 Dec 1;137(11):3414–3419. [PubMed]
  • Seaman WE, Wofsy D, Greenspan JS, Ledbetter JA. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J Immunol. 1983 Apr;130(4):1713–1718. [PubMed]
  • Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol. 1983 Dec;131(6):2895–2902. [PubMed]
  • Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol. 1987 May 15;138(10):3247–3253. [PubMed]
  • Izui S, McConahey PJ, Dixon FJ. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J Immunol. 1978 Dec;121(6):2213–2219. [PubMed]
  • Klinman DM, Steinberg AD. Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med. 1987 Jun 1;165(6):1755–1760. [PMC free article] [PubMed]
  • Steward MW, Hay FC. Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice. Clin Exp Immunol. 1976 Nov;26(2):363–370. [PMC free article] [PubMed]
  • Carteron NL, Schimenti CL, Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol. 1989 Mar 1;142(5):1470–1475. [PubMed]
  • Isaacs JD. The antiglobulin response to therapeutic antibodies. Semin Immunol. 1990 Nov;2(6):449–456. [PubMed]
  • Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol. 1986 Aug 15;137(4):1127–1132. [PubMed]
  • Benjamin RJ, Cobbold SP, Clark MR, Waldmann H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med. 1986 Jun 1;163(6):1539–1552. [PMC free article] [PubMed]
  • Benjamin RJ, Qin SX, Wise MP, Cobbold SP, Waldmann H. Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur J Immunol. 1988 Jul;18(7):1079–1088. [PubMed]
  • Staples PJ, Talal N. Rapid loss of tolerance induced in weanling NZB and B-W F1 mice. Science. 1969 Mar 14;163(3872):1215–1216. [PubMed]
  • Staples PJ, Steinberg AD, Talal N. Induction of immunologic tolerance in older New Zealand mice repopulated with young spleen, bone marrow, or thymus. J Exp Med. 1970 Jun 1;131(6):1223–1238. [PMC free article] [PubMed]
  • Staples PJ, Talal N. Relative inability to induce tolerance in adult NZB and NZB-NZW F1 mice. J Exp Med. 1969 Jan 1;129(1):123–139. [PMC free article] [PubMed]
  • Starnes HF, Jr, Pearce MK, Tewari A, Yim JH, Zou JC, Abrams JS. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol. 1990 Dec 15;145(12):4185–4191. [PubMed]
  • Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 1993 Feb;20(2):259–262. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...